Abstract
Background
One week of Helicobacter pylori eradication therapy is insufficient for healing of gastric ulcers. We examined the efficacy of rebamipide in gastric ulcer healing following 1 week of eradication therapy in a randomized, double-blind, placebo-controlled trial.
Methods
Patients with H. pylori-positive gastric ulcer were enrolled and received 1 week of eradication therapy, followed by 100 mg of rebamipide or placebo for 7 weeks. The primary end point was the gastric ulcer healing rate.
Results
Of the 309 patients entered in the trial, 301 completed H. pylori eradication therapy; 154 patients took rebamipide, and 147 took placebo. The healing rate in the rebamipide group was higher than that in the placebo group in the per-protocol analysis—80.0% (104/130) versus 66.1% (82/124) [95% confidence interval (CI), 3.1–24.7; P = 0.013)—and in a full analysis—70.1% (108/154) versus 60.5% (89/147) (95% CI, −1.1 to 20.3; P = 0.080).
Conclusions
Compared with placebo, rebamipide significantly promoted gastric ulcer healing following 1 week of eradication therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
P Malfertiner FO Megraud C Morain A Hungin R Jones A Axon et al. (2002) ArticleTitleThe European Helicobacter pylori Study Group. Current concepts in the management of H. pylori infection: the Maastricht 2 2000 Consensus Report Aliment Pharmacol Ther 16 167–80 Occurrence Handle10.1046/j.1365-2036.2002.01169.x
M Asaka K Satoh K Sugano T Sugiyama S Takahashi Y Fukuda et al. (2001) ArticleTitleGuidelines in the management of Helicobacter pylori infection in Japan Helicobacter 6 177–86 Occurrence Handle11683920 Occurrence Handle10.1046/j.1523-5378.2001.00027.x Occurrence Handle1:STN:280:DC%2BD3MnjsFalsA%3D%3D
R Hulst E Rauws B Koych B Koyuu J Keller M Bruno et al. (1997) ArticleTitlePrevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study Gastroenterology 113 1082–6 Occurrence Handle9322501 Occurrence Handle10.1053/gast.1997.v113.pm9322501
JP Gisbert JM Pajares (2005) ArticleTitleSystematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 21 795–804 Occurrence Handle15801914 Occurrence Handle10.1111/j.1365-2036.2005.02418.x Occurrence Handle1:CAS:528:DC%2BD2MXjvVykt78%3D
K Higuchi K Fujiwara K Tominaga M Watanabe S Shiba S Nakamura et al. (2003) ArticleTitleIs eradication sufficient to heal gastric ulcer in patients infected with Helicobacter pylori? A randomized, controlled, prospective study Aliment Pharmacol Ther 17 111–7 Occurrence Handle12492739 Occurrence Handle10.1046/j.1365-2036.2003.01402.x Occurrence Handle1:STN:280:DC%2BD38jjtVSltQ%3D%3D
K Higuchi T Arakawa H Nebiki T Uchida Y Fujiwara K Ando et al. (1998) ArticleTitleRebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status Dig Dis Sci 43 99S–106S Occurrence Handle9753234 Occurrence Handle1:CAS:528:DyaK1cXmsV2rsLs%3D
A Terano T Arakawa T Sugiyama T Yoshikawa K Haruma M Asaka et al. (2006) ArticleTitleA pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastro-protective treatment with rebamipide J Gastroenterol Hepatol 21 103–9 Occurrence Handle16706820 Occurrence Handle10.1111/j.1440-1746.2005.04191.x Occurrence Handle1:CAS:528:DC%2BD28XhtlajsLjN
K Murakami T Fujioka T Okimoto R Sata M Kodama M Nasu (2002) ArticleTitleDrug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy Int J Antimicrob Agents 19 67–70 Occurrence Handle11814770 Occurrence Handle10.1016/S0924-8579(01)00456-3 Occurrence Handle1:CAS:528:DC%2BD38Xos1Cjsw%3D%3D
K Yamasaki T Kanbe T Chijiwa H Ishiyama S Morita (1987) ArticleTitleGastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat Eur J Pharmacol 142 23–9 Occurrence Handle3480223 Occurrence Handle10.1016/0014-2999(87)90649-2 Occurrence Handle1:CAS:528:DyaL1cXhs1Wjsw%3D%3D
AS Tarnawski J Chai R Pai SK Chiou (2004) ArticleTitleRebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 49 202–9 Occurrence Handle15104358 Occurrence Handle10.1023/B:DDAS.0000017439.60943.5c Occurrence Handle1:CAS:528:DC%2BD2cXhsFOhu78%3D
H Miwa N Sakaki K Sugano H Sekine K Higuchi N Uemura et al. (2004) ArticleTitleRecurrence peptic ulcer in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients Helicobacter 9 9–16 Occurrence Handle15156899 Occurrence Handle10.1111/j.1083-4389.2004.00194.x
K Murakami R Sato T Okimoto K Watanabe M Nasu T Fujioka et al. (2003) ArticleTitleInfluence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection J Gastroenterol 38 937–41 Occurrence Handle14614600 Occurrence Handle10.1007/s00535-003-1176-x Occurrence Handle1:CAS:528:DC%2BD3sXovVKnu7c%3D
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Terano, A., Arakawa, T., Sugiyama, T. et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 42, 690–693 (2007). https://doi.org/10.1007/s00535-007-2076-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-007-2076-2